AR110351A1 - COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa - Google Patents
COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNaInfo
- Publication number
- AR110351A1 AR110351A1 ARP170103473A ARP170103473A AR110351A1 AR 110351 A1 AR110351 A1 AR 110351A1 AR P170103473 A ARP170103473 A AR P170103473A AR P170103473 A ARP170103473 A AR P170103473A AR 110351 A1 AR110351 A1 AR 110351A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ifna
- heteroarilo
- phosphinoxide
- rented
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 150000003004 phosphinoxides Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 230000011234 negative regulation of signal transduction Effects 0.000 abstract 1
- WCYWZMWISLQXQU-FIBGUPNXSA-N trideuteriomethane Chemical group [2H][C]([2H])[2H] WCYWZMWISLQXQU-FIBGUPNXSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433470P | 2016-12-13 | 2016-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110351A1 true AR110351A1 (es) | 2019-03-20 |
Family
ID=60888685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103473A AR110351A1 (es) | 2016-12-13 | 2017-12-12 | COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10294256B2 (enExample) |
| EP (1) | EP3555111B1 (enExample) |
| JP (1) | JP7046092B2 (enExample) |
| KR (1) | KR102602558B1 (enExample) |
| CN (1) | CN110267964B (enExample) |
| AR (1) | AR110351A1 (enExample) |
| ES (1) | ES2907008T3 (enExample) |
| MA (1) | MA48602A (enExample) |
| TW (1) | TW201827423A (enExample) |
| WO (1) | WO2018111787A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7258903B2 (ja) | 2017-11-21 | 2023-04-17 | ブリストル－マイヤーズ スクイブ カンパニー | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 |
| AU2019234574A1 (en) | 2018-03-12 | 2020-09-03 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| CN111936486B (zh) * | 2018-03-22 | 2023-09-22 | 百时美施贵宝公司 | 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物 |
| US20230049130A1 (en) * | 2020-01-19 | 2023-02-16 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Deucravacitinib crystal form, preparation method therefor and use thereof |
| CN119954775A (zh) | 2020-12-22 | 2025-05-09 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| CN117083268B (zh) | 2021-03-16 | 2024-07-30 | 安锐生物医药科技(广州)有限公司 | 氨基杂芳基化合物和组合物 |
| CN115724830A (zh) * | 2021-08-31 | 2023-03-03 | 浙江文达医药科技有限公司 | 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法 |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060270730A1 (en) * | 2003-08-07 | 2006-11-30 | Andreas Katopodis | Histone deacetylase inhibitors as immunosuppressants |
| ES2645689T5 (en) * | 2008-05-21 | 2025-06-24 | Takeda Pharmaceuticals Co | Phosphorous derivatives as kinase inhibitors |
| TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| JP5957537B2 (ja) * | 2011-12-21 | 2016-07-27 | ビオタ ヨーロッパ リミテッドＢｉｏｔａ Ｅｕｒｏｐｅ Ｌｔｄ | 複素環式ウレア化合物 |
| JP6469567B2 (ja) * | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| EA028526B1 (ru) * | 2012-11-08 | 2017-11-30 | Бристол-Майерс Сквибб Компани | АЛКИЛАМИДЗАМЕЩЕННЫЕ ПИРИДИЛЬНЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα |
| DK2922846T3 (en) | 2012-11-08 | 2019-01-21 | Bristol Myers Squibb Co | AMID-SUBSTITUTED HETEROCYCLIC COMPOUNDS USED AS MODULATORS OF IL-12, IL-23 AND / OR IFN-ALPHA |
| WO2014181287A1 (en) * | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| AR094537A1 (es) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| EP2947460A1 (en) * | 2014-05-22 | 2015-11-25 | Medizinische Universität Wien | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists |
-
2017
- 2017-12-12 WO PCT/US2017/065665 patent/WO2018111787A1/en not_active Ceased
- 2017-12-12 EP EP17822919.1A patent/EP3555111B1/en active Active
- 2017-12-12 CN CN201780086194.3A patent/CN110267964B/zh active Active
- 2017-12-12 AR ARP170103473A patent/AR110351A1/es unknown
- 2017-12-12 KR KR1020197019993A patent/KR102602558B1/ko active Active
- 2017-12-12 ES ES17822919T patent/ES2907008T3/es active Active
- 2017-12-12 US US15/838,434 patent/US10294256B2/en active Active
- 2017-12-12 MA MA048602A patent/MA48602A/fr unknown
- 2017-12-12 TW TW106143529A patent/TW201827423A/zh unknown
- 2017-12-12 JP JP2019551913A patent/JP7046092B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201827423A (zh) | 2018-08-01 |
| KR102602558B1 (ko) | 2023-11-14 |
| US20180162889A1 (en) | 2018-06-14 |
| EP3555111B1 (en) | 2022-01-26 |
| JP7046092B2 (ja) | 2022-04-01 |
| MA48602A (fr) | 2020-03-18 |
| CN110267964B (zh) | 2022-05-03 |
| WO2018111787A1 (en) | 2018-06-21 |
| ES2907008T3 (es) | 2022-04-21 |
| CN110267964A (zh) | 2019-09-20 |
| US10294256B2 (en) | 2019-05-21 |
| KR20190091536A (ko) | 2019-08-06 |
| EP3555111A1 (en) | 2019-10-23 |
| JP2020502268A (ja) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110351A1 (es) | COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR119454A2 (es) | COMPUESTOS ÚTILES COMO MODULADORES DE RORg, SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS Y DICHOS COMPUESTOS PARA USO COMO MEDICAMENTO | |
| AR119761A2 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| CL2020001338A1 (es) | Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona. | |
| CU20170015A7 (es) | Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il | |
| UY36121A (es) | ?pirazolopiridinas y pirazolopirimidinas?. | |
| EA201790922A1 (ru) | Ингибиторы бромодомена | |
| EA201591491A1 (ru) | Соединения тетрагидропирролотиазина | |
| EA201790328A1 (ru) | Диоксолановые аналоги уридина для лечения рака | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR091273A1 (es) | Inhibidores de pirimidinil tirosina quinasa | |
| AR099400A1 (es) | Compuesto heterocíclico fusionado | |
| AR102171A1 (es) | Compuestos sustituidos de aminopurina, sus composiciones y su uso en el tratamiento o prevención de melanoma | |
| CY1122563T1 (el) | ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγt | |
| EA201790343A1 (ru) | Способ получения сульфамидных производных пиримидина | |
| EA201891562A2 (ru) | ТРИФТОРМЕТИЛОВЫЕ СПИРТЫ КАК МОДУЛЯТОРЫ RORγt | |
| AR109706A1 (es) | INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g | |
| EA201592268A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 | |
| AR102256A1 (es) | Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi | |
| SI3833665T1 (sl) | Diazabiciklooktanoni kot zaviralci serinskih beta-laktamaz | |
| EP4080980C0 (en) | PLANNING REQUEST INDICATION | |
| IL269695A (en) | Compounds useful as inhibitors of alcat 1 | |
| EP3667511C0 (en) | NON-UNIFORM PAGINATION OF DATA IN COLUMNS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |